47 results on '"Dorr, Casey"'
Search Results
2. Implementing community-engaged pharmacogenomics in Indigenous communities
3. Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers.
4. Pharmacomicrobiomics: Immunosuppressive Drugs and Microbiome Interactions in Transplantation
5. Pharmacogenomics in kidney transplant recipients and potential for integration into practice.
6. Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.
7. Analysis of 75 Candidate SNPs Associated With Acute Rejection in Kidney Transplant Recipients: Validation of rs2910164 in MicroRNA MIR146A.
8. Genetic Variants Associated With Immunosuppressant Pharmacokinetics and Adverse Effects in the DeKAF Genomics Genome-wide Association Studies.
9. Extreme Phenotype Sampling and Next Generation Sequencing to Identify Genetic Variants Associated with Tacrolimus in African American Kidney Transplant Recipients
10. CRISPR/Cas9 Genetic Modification of CYP3A5 *3 in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism.
11. Polygenic risk score for acute rejection based on donor-recipient non-HLA genotype mismatch.
12. Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients.
13. American Indian Perspectives on Culturally Aligning a Digital Smoking Cessation Resource
14. Opportunities and challenges for immunosuppression in the context of pig-to-human xenotransplantation
15. Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing
16. American Indian Perspectives on Culturally Aligning a Digital Smoking Cessation Resource.
17. Supplemental Table S2 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
18. Data from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
19. Supplemental Information from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
20. Figures S1 through S7 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
21. Table S1 and S3 through S10 from Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
22. Concepts of Genomics in Kidney Transplantation
23. Genome-Wide Association Meta-Analysis for Acute Rejection of Kidney Transplants
24. Genetics of acute rejection after kidney transplantation
25. Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe
26. Exploring Potential for a Personalized Medicine Approach to Smoking Cessation With an American Indian Tribe.
27. Precision Dosing for Tacrolimus Using Genotypes and Clinical Factors in Kidney Transplant Recipients of European Ancestry
28. Pharmacogenomics in kidney transplant recipients and potential for integration into practice
29. Genetic variants associated with immunosuppressant pharmacokinetics and adverse effects in the DeKAF genomics genome-wide association studies
30. 487 Digital Spatial Profiling of Allograft Loss in Kidney Biopsies with Chronic Allograft Dysfunction.
31. Tacrolimus trough and dose intra-patient variability and CYP3A5 genotype: Effects on acute rejection and graft failure in European American and African American kidney transplant recipients
32. Tacrolimus Elimination in Four Patients With aCYP3A5*3/*3 CYP3A4*22/*22Genotype Combination
33. Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients
34. Genetics of acute rejection after kidney transplantation
35. Association Between Mycophenolic Acid (MPA) Pharmacokinetics and In Vitro MPA Glucuronide (MPAG) Turnover by Gut Microbiota of Kidney Transplant Recipients
36. Variability in Commensal Gut Microbiota Associated with Tacrolimus Metabolism in a Longitudinal Kidney Transplant Cohort Study
37. Genetic Variants Associated with Tacrolimus Metabolism in Kidney Transplant Recipients
38. Deceased-Donor Apolipoprotein L1 Renal-Risk Variants Have Minimal Effects on Liver Transplant Outcomes
39. Transposon Mutagenesis Screen Identifies Potential Lung Cancer Drivers and CUL3 as a Tumor Suppressor
40. Triterpene derivatives that inhibit human immunodeficiency virus type 1 replication
41. Abstract C43: A Sleeping Beauty forward genetic screen identifies novel cancer drivers that cooperate with Pten in lung cancer
42. Abstract 108: Functional characterization of WAC, a candidate tumor suppressor gene in colorectal cancer
43. CRISPR/Cas9 Genetic Modification of CYP3A5 *3in HuH-7 Human Hepatocyte Cell Line Leads to Cell Lines with Increased Midazolam and Tacrolimus Metabolism
44. Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes.
45. Compounds derived from birch trees that inhibit HIV-1 replication
46. Limited Sampling Strategies Fail to Accurately Predict Mycophenolic Acid Area Under the Curve in Kidney Transplant Recipients and the Impact of Enterohepatic Recirculation.
47. Extreme Phenotype Sampling and Next Generation Sequencing to Identify Genetic Variants Associated with Tacrolimus in African American Kidney Transplant Recipients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.